Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,689 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Results available

Oxytocin Dosage to Decrease Induction Duration

NCT03140488
Conditions
Obesity, Labor, Induced, Oxytocin
Interventions
Oxytocin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Osteoarthritis, Knee, Microfragmented Adipose Tissue, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma
Device
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Ischemic Stroke
Interventions
Verapamil and Citicoline, Placebo
Drug · Other
Lead sponsor
Justin Fraser
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Atibuclimab, Placebo
Biological · Other
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Candidiasis
Interventions
Caspofungin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Conditions
Postoperative Pain
Interventions
Bupivicaine Infusion
Drug
Lead sponsor
Chang, Steve S., M.D.
Individual
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Santa Barbara, California
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Conditions
Common Cold
Interventions
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Mesothelioma
Interventions
Magnesium sulfate, Normal Saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy

NCT02104414
Conditions
Hemorrhoid
Interventions
Exparel, Bupivacaine HCl with Epinephrine, Normal Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Glycogen Storage Disease Type IA
Interventions
DTX401, Placebo, Oral prednisolone, Placebo for oral prednisolone
Genetic · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
8 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more
Conditions
Myringotomy
Interventions
Dexmedetomidine
Drug
Lead sponsor
Martin Mueller
Other
Eligibility
1 Year to 10 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
HIV Infections
Interventions
VSV-Indiana HIV gag vaccine, Placebo injection (normal saline)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

NCT00387621
Conditions
Congestive Heart Failure
Interventions
Nesiritide, Placebo, Saline
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Idiopathic Scoliosis, Spondylolisthesis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Julia Finkel
Other
Eligibility
10 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed No phase listed Observational Accepts healthy volunteers

Vaginal Innate Immunity in Normal and HIV-Infected Women

NCT01318304
Conditions
HIV, Pregnancy
Interventions
Vaginal lavage specimen
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

NCT02516904
Conditions
Healthy
Interventions
CD101 IV, Placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Minimizing Nausea and Vomiting During Spinals for CS

NCT02872935
Conditions
Nausea, Vomiting
Interventions
Glycopyrrolate, Normal Saline
Drug
Lead sponsor
Kokila N Thenuwara
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Malignant Neoplasms of Brain
Interventions
PEP-3-KLH conjugate vaccine, daclizumab, temozolomide, placebo, PEP-3-KLH
Biological · Drug · Other
Lead sponsor
John Sampson
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pancreatic Cyst, EUS-FNA
Interventions
Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Hershey, Pennsylvania